BUSINESS● LOWSep 24 · Sep 24, 2026, 2:26 PM
Arcturus raised to Buy at Citi after mid-stage trial data for liver disease drug
Seeking Alpha Tech · global
Citi has upgraded Arcturus's stock rating to "Buy" following the release of mid-stage trial data for its liver disease drug. This indicates a positive outlook on the company's pharmaceutical development and market performance.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS13m agoOffer in Compromise , Installment Agreement or Currently Not Collectible : Helping Clients Pick the Right IRS Pathcpapracticeadvisor.com · United StatesBUSINESS13m agoGarth Brooks Halts Ticket Sales for Upcoming Show Due to Botskdhlradio.com · United States